A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies
Conditions: Hematologic Malignancy; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin Intervention: Biological: CAR-37 T cells Sponsor: Marcela V. Maus, M.D.,Ph.D. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials